Home/Rare Diseases/Pemphigus Vulgaris

Dermatologic

Pemphigus Vulgaris

Also called PV, Caebra Selvatica, Pemphigus Vulgaris Acutus

Pemphigus Vulgaris is an autoimmune blistering disease characterized by production of IgG autoantibodies against desmogleins, adhesion molecules essential for cell-to-cell adhesion. Antibodies target primarily desmoglein 3 (mucosal involvement) and sometimes also desmoglein 1 (mucocutaneous disease).

View active trialsMatch me to a trial

About Pemphigus Vulgaris

Pemphigus Vulgaris is an autoimmune blistering disease characterized by production of IgG autoantibodies against desmogleins, adhesion molecules essential for cell-to-cell adhesion. Antibodies target primarily desmoglein 3 (mucosal involvement) and sometimes also desmoglein 1 (mucocutaneous disease). Antibody binding disrupts cell adhesion, leading to acantholysis (loss of cell-to-cell adhesion) and intraepidermal blister formation. Clinically, patients typically present with painful oral erosions and ulcerations, often the initial manifestation. Flaccid blisters then develop on skin, characteristically rupturing easily to leave painful, slow-healing erosions. The condition can become severe with extensive erosions affecting eating, breathing, and ability to care for self-care. Erosions are susceptible to secondary bacterial infection, leading to sepsis risk. Suprabasal acantholysis (within lower epidermis) is characteristic histopathology. In mucosal-dominant disease, oral involvement predominates. In mucocutaneous disease, both oral and skin involvement occurs. Untreated disease was historically fatal, with mortality from secondary infection or malnutrition.

Common Symptoms

  • Painful blisters and erosions in mouth, often first sign
  • Flaccid blisters on skin that rupture easily
  • Painful erosions on face, scalp, chest, and genital area
  • Loss of appetite from oral involvement
  • Secondary infections of eroded areas
  • Systemic symptoms from extensive involvement

Who It Affects

Pemphigus Vulgaris typically manifests in adults aged 40-60 years, though it can develop at any age. It affects males and females roughly equally. The disease is more common in people of Mediterranean, Jewish (Ashkenazi Jewish particularly), and Indian ancestry. It is associated with certain HLA types. There is no strong genetic predisposition in most cases, and it is considered an acquired autoimmune disease.

Getting Involved in Clinical Trials

Clinical trials for Pemphigus Vulgaris focus on corticosteroid-sparing immunosuppressive strategies, including azathioprine, mycophenolate mofetil, and rituximab (anti-B cell monoclonal antibody). Trials investigate rituximab monotherapy and combination approaches that may allow dose reduction or discontinuation of systemic corticosteroids. Newer biologic therapies targeting T cells and other immune pathways are under investigation. Management requires monitoring for corticosteroid toxicity and infections. Patients should consult with a dermatologist experienced in autoimmune blistering diseases.

Trusted Sources

Active Clinical Trials for Pemphigus Vulgaris

Finding trials for Pemphigus Vulgaris...

Related Dermatologic Conditions

Dermatologic

Morphea

Morphea is a localized form of scleroderma characterized by hardened patches of skin with hyperpigmentation or hypopigme...